<?xml version="1.0" encoding="UTF-8"?>
<p id="Par54">In China, the recommended first-line regimen was zidovudine (AZT) or stavudine (D4T) + lamivudine (3TC) + nevirapine (NVP) in 2005 [
 <xref ref-type="bibr" rid="CR22">22</xref>] and D4T was gradually replaced by AZT or tenofovir (TDF) from 2010 [
 <xref ref-type="bibr" rid="CR37">37</xref>]. The current first-line regimen was TDF or AZT + 3TC + efavirenz (EFV) or NVP [
 <xref ref-type="bibr" rid="CR15">15</xref>]. This study indicated that the HIVDR was high in the high prevalence regions, even though these patients without antiretroviral drugs exposure. The most common DRMs were related these drugs being used in China. Hence, the DRMs in treatment-naïve patients may originate from treatment failure.
</p>
